Glucose Counterregulation in Long Standing Type 1 Diabetes

Healthy Clinical Trial

Official title:

Effect of Real-Time Continuous Glucose Monitoring on Glucose Counterregulation in Long Standing Type 1 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01474889
• Other study ID #: 814114
• Secondary ID: R01DK091331-01
• Status: Completed
• Phase: N/A
• Start date: October 2011
• Est. completion date: March 5, 2021

Study information

• Verified date: August 2023
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Enrollment for this study is complete.

This study is designed to determine if use of a real-time continuous glucose monitor (RT-CGM) can reverse defective Glucose counter regulation and hypoglycemia unawareness in long standing type 1 diabetes.

Description:

The present protocol is designed to determine whether strict hypoglycemia avoidance by real-time continuous glucose monitoring (RT-CGM), can restore endogenous glucose production in response to hypoglycemia in patients with long standing disease. Twelve subjects with long standing type 1 diabetes complicated by hypoglycemia unawareness underwent assessment of the endogenous glucose production response to insulin-induced hypoglycemia using paired hyperinsulinemic euglycemic and hypoglycemic clamps with stable glucose isotope infusions before and at 6 and 18 months following initiation of RT-CGM. The primary analysis will be change in the endogenous glucose production response from before to 6 months following initiation of RT-CGM, and a secondary analysis will consider the persistence of any change at 18 months. The clinical significance of any determined changes in the endogenous glucose production response to insulin-induced hypoglycemia will be determined by comparison to responses obtained using paired hyperinsulinemic euglycemic and hypoglycemic clamps on one occasion in a matched control group of 12 subjects with long-standing type 1 diabetes but no hypoglycemia unawareness (GROUP 2) and in a matched control group of 12 nondiabetic subjects (GROUP 3).

Arms are not assigned to these two control groups in ct.gov as they were only used as a baseline for clinical significance. Neither group wore a CGM nor are they analyzed at 6-month and 18-month time-points. This said, for control group clarification, inclusion and exclusion criteria for each group is included in ct.gov

Hypoglycemia is a major barrier to the achievement of adequate glycemic control for most patients with insulin-dependent diabetes. Type 1 diabetic patients with absolute insulin deficiency (C-peptide negative) are at greatest risk for experiencing severe hypoglycemic events because the near total destruction of insulin producing islet β-cells produces an associated defect in glucagon secretion from neighboring α-cells. Such patients then depend on the sympathoadrenal system as a final defense against hypoglycemia, but unfortunately, recurrent episodes of hypoglycemia blunt sympathoadrenal activation and produce a syndrome of hypoglycemia unawareness that is associated with a twenty-fold increased risk of life-threatening hypoglycemia. Without intact islet or sympathoadrenal (especially epinephrine) responses to hypoglycemia, these patients cannot increase endogenous (primarily hepatic) glucose production to prevent or correct low blood glucose.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: March 5, 2021
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 70 Years

Eligibility

Key Inclusion Criteria for intervention GROUP 1 (Long-standing T1D complicated by hypoglycemia unawareness)

1. Male and female subjects aged 25 to 70 years

2. Able to provide written informed consent and to comply with the protocol procedures

3. Clinical history compatible with type 1 diabetes with disease onset < 40 years of age OR onset = 40 years and documented islet autoimmunity

4. Insulin-dependent for > 10 years

5. Absent C-peptide (< 0.3 ng/mL).

6. Involvement in intensive diabetes management defined as self-monitoring of glucose values no less than a mean of three times each day averaged over each week and by the administration of three or more insulin injections each day or insulin pump therapy under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least 3 clinical evaluations during the previous 12 months.)

7. Hypoglycemia unawareness manifested by a Clarke score of 4 or more AND at least one of the following:

• HYPO score greater than or equal to the 90th percentile (1047); OR marked glycemic lability defined by a glycemic lability index (LI) score greater than or equal to the 90th percentile (433 mmol/l2/h·wk-1); OR

• A composite of a HYPO score greater than or equal to the 75th percentile (423) and a LI greater than or equal to the 75th percentile (329).

8. At least one episode of severe hypoglycemia in the past 12 months defined as an event with symptoms or signs compatible with hypoglycemia in which the subject was unable to treat him/herself and which was associated with either a blood glucose level < 54 mg/dl [3.0 mmol/L] or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration; OR documented > 5% time spent in the hypoglycemic range (glucose < 60 mg/dl) by 72-hour blinded CGM.

Key Inclusion Criteria for control GROUP 2 (Long-standing T1D with intact hypoglycemia awareness)

1. Male and female subjects aged 25 to 70 years.

2. Able to provide written informed consent and to comply with the procedures of the study protocol.

3. Clinical history compatible with type 1 diabetes with disease onset < 40 years of age

4. Insulin-dependent for > 10 years

5. Absent C-peptide (< 0.3 ng/mL).

6. Involvement in intensive diabetes management defined as the use of basal-bolus insulin analog delivery by multi-dose injection (MDI) or continuous subcutaneous insulin infusion (CSII) together with self-monitoring of blood glucose values four or more times daily, without continuous glucose monitoring (CGM), under the direction of an endocrinologist, diabetologist, or diabetes nurse practitioner with at least 3 clinical evaluations during the previous 12 months.

7. Intact hypoglycemia awareness indicated by a Clarke score of 3 or less.

8. No episodes of severe hypoglycemia in the past 3 years.

Key Inclusion Criteria for control GROUP 3 (Non-diabetic controls)

1. Male and female subjects aged 25 to 70 years.

2. Subjects who are able to provide written informed consent and to comply with the procedures of the study protocol.

3. No history of diabetes.

Key Exclusion Criteria for ALL 3 groups

1. Body mass index (BMI) greater than 38 kg/m2.

2. Insulin requirement of more than 1.0 IU/kg/day.

3. HbA1c greater than 10%.

4. Untreated proliferative diabetic retinopathy.

5. SBP greater than 160 mmHg or DBP greater than 100 mmHg.

6. Glomerular filtration rate (GFR) less than 55 ml/min/1.73 m-squared

7. Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study.

8. Baseline hemoglobin less than 11 g/dl in women and less than12 g/dl in men.

9. Severe co-existing cardiac disease

10. Persistent elevation of liver function tests greater than 1.5 upper normal limits

11. Hyperlipidemia despite medical therapy

12. Receiving treatment for a medical condition requiring chronic use of systemic steroids

13. Presence of a seizure disorder not attributable to hypoglycemia.

14. Untreated hypothyroidism, Addisons disease, or Celiac disease.

15. Treatment with any anti-diabetic medication other than insulin within 4 weeks of enrollment.

16. Use of RT-CGM (continuous glucose monitor) within last 4 weeks.

• Non-diabetic patients do not need to meet any of the glucose criteria.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Healthy
• Hypoglycemia
• Hypoglycemia Unawareness
• Type 1 Diabetes
• Unconsciousness

Intervention

Device:
• RT-CGM
Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.

Locations

Country	Name	City	State
United States	Clinical and Translational Research Center, Hospital of University of Pennsylvania	Philadelphia	Pennsylvania
United States	Rodebaugh Diabetes Center, University of Pennsylvania	Philadelphia	Pennsylvania
United States	University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
University of Pennsylvania	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

References & Publications (10)

Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005 Dec;54(12):3592-601. doi: 10.2337/diabetes.54.12.3592. — View Citation

Hermanides J, Norgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, Diem P, Fermon C, Wentholt IM, Hoekstra JB, DeVries JH. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med. 2011 Oct;28(10):1158-67. doi: 10.1111/j.1464-5491.2011.03256.x. — View Citation

Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther. 2008 Oct;10(5):377-83. doi: 10.1089/dia.2008.0068. — View Citation

Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes. 1997 Feb;46(2):271-86. — View Citation

JDRF CGM Study Group. JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods. Diabetes Technol Ther. 2008 Aug;10(4):310-21. doi: 10.1089/dia.2007.0302. — View Citation

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008 Oct 2;359(14):1464-76. doi: 10.1056/NEJMoa0805017. Epub 2008 Sep 8. — View Citation

Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jorgensen HV, Matthews DR, Hougaard P, Thorsteinsson B. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev. 2004 Nov-Dec;20(6):479-86. doi: 10.1002/dmrr.482. — View Citation

Rickels MR, Schutta MH, Mueller R, Kapoor S, Markmann JF, Naji A, Teff KL. Glycemic thresholds for activation of counterregulatory hormone and symptom responses in islet transplant recipients. J Clin Endocrinol Metab. 2007 Mar;92(3):873-9. doi: 10.1210/jc.2006-2426. Epub 2006 Dec 27. — View Citation

Rickels MR, Schutta MH, Mueller R, Markmann JF, Barker CF, Naji A, Teff KL. Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes. Diabetes. 2005 Nov;54(11):3205-11. doi: 10.2337/diabetes.54.11.3205. — View Citation

Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP, Tobian J, Gross T, Mastrototaro J. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004 Dec;79(12):1521-6. doi: 10.4065/79.12.1521. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Endogenous Glucose Production	Measure of hepatic glucose output during final hour of hypoglycemic clamp.; Outcome Measures are not assigned to the control groups in ct.gov as they were only used as a baseline for clinical significance. Neither group wore a CGM nor were they analyzed at 6-month and 18-month time-points.	6 months
Secondary	Endogenous Glucose Production	Measure of hepatic glucose output during final hour of hypoglycemic clamp	18 months
Secondary	Autonomic Symptom Response to Hypoglycemia	Response measure during hypoglycemic clamp using an Autonomic Symptom Questionnaire.; The autonomic symptom response is calculated during the final hour of the Hypoglycemic clamp as the sum of scores ranging from 0 (none) to 5 (severe) for each of the following symptoms: anxiety, palpitations, sweating, tremor, hunger, and tingling. This results in a minimum of 0 or a maximum of 30 score with the higher score a better outcome. The scale title is Autonomic Symptom Response to hypoglycemia.	6 months
Secondary	Autonomic Symptom Response to Hypoglycemia	Response measure during hypoglycemic clamp using an Autonomic Symptom Questionnaire.; The autonomic symptom response is calculated during the final hour of the Hypoglycemic clamp as the sum of scores ranging from 0 (none) to 5 (severe) for each of the following symptoms: anxiety, palpitations, sweating, tremor, hunger, and tingling. This results in a minimum of 0 or a maximum of 30 score with the higher score a better outcome. The scale title is Autonomic Symptom Response to hypoglycemia.	18 months